

Ref. No: 009010422
From: Commercial
Date: 01/04/22
Subject: Lung Cancer Treatment

REQUEST

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

- Afatinib
- Alectinib
- Atezolizumab monotherapy
- Atezolizumab in combination
- Bevacizumab
- Brigatinib
- Capmatenib
- Ceritinib
- Crizotinib
- Dacomitinib
- Dabrafenib with Trametinib
- Docetaxel monotherapy
- Durvalumab

- Erlotinib
- Gefitinib
- Gemcitabine
- Nintedanib with Docetaxel
- Nivolumab
- Osimertinib
- Paclitaxel
- Pembrolizumab monotherapy
- Pembrolizumab in combination
- Pemetrexed with Carboplatin/Cisplatin
- Tepotinib
- Vinorelbine with Cisplatin/Carboplatin
- Any other SACT
- Palliative care only

RESPONSE

- St Helens & Knowsley Teaching Hospitals Trust does not hold this information as chemotherapy treatment is carried out at Clatterbridge Cancer centre NHS Foundation Trust. Please re-direct your request to The Clatterbridge Cancer Centre NHS Foundation Trust

Contact Details are as follows:

The Clatterbridge Cancer Centre NHS Foundation Trust

Clatterbridge Road

Bebington

Wirral

CH63 4JY

Tel 0151 556 5000

- St Helens and Knowsley has treated <5 metastatic non-small cell lung cancer (NSCLC) patients during a 3month period (01/12/21 – 28/02/2022)

Please note <5 has been added where the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients can not be identified.

- Based on histology code 128632008
- Based on patients with a M1 stage